Metabolism studies of desvenlafaxine

Journal of Bioequivalence and Bioavailability

Volumn 3, Issue 7, 2011, Pages 151-160

  Demaio, William ^a   Kane, Cecelia P ^a   Nichols, Alice I ^a   Jordan, Ronald ^a  

^a PFIZER INC   (United States)

Author keywords

Cytochrome P450; Desvenlafaxine; Drug metabolism; Drug drug interactions; Major depressive disorder

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DESVENLAFAXINE; DESVENLAFAXINE O GLUCURONIDE; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DOG; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; RADIOACTIVITY; RANDOMIZED CONTROLLED TRIAL; RAT;

EID: 80052384293     PISSN: None     EISSN: 09750851     Source Type: Journal    
DOI: 10.4172/jbb.1000076     Document Type: Article

References (24)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, et al. (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 593-602.
2. Andrews G (2001) Should depression be managed as a chronic disease? BMJ 322: 419-421.
3. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, et al. (2006) Evaluation of outcomes with citalopram for depression using measurementbased care in STAR*D: implications for clinical practice. Am J Psychiatry 163: 28-40.
4. Masand PS (2003) Tolerability and adherence issues in antidepressant therapy. Clin Ther 25: 2289-2304.
5. Center for Drug Evaluation and Research, US Food and Drug Administration, Office of Generic Drugs (2008) Approved drug products with therapeutic equivalence evaluations, cumulative supplement 11. (28th ed) Center for Drug Evaluation and Research; US Food and Drug Administration; Office of Generic Drugs, Bethesda, MD.
6. Pristiq [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2009.
7. Speroff L, Gass M, Constantine G, Olivier S (2008) Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 111: 77-87.
8. Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S (2009) A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 200: 172.e1-172.e10.
9. Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S (2009) Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 200: 238.e1-238.e10.
10. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, et al. (2006) Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 318: 657-665.
11. Howell SR, Husbands GE, Scatina JA, Sisenwine SF (1993) Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 23: 349-359.
12. Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, et al. (2008) Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 23: 243-253.
13. Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, et al. (2008) Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 24: 1877-1890.
14. Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D (2009) Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebocontrolled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther 31: 1405-1423.
15. Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, et al. (2006) CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 31: 493-502.
16. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, et al. (2001) A method for the simultaneous evaluation of the activities of seven major human drugmetabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 29: 23-29.
17. Lake BG (1987) Preparation and characterisation of microsomal fractions for studies on xenobiotic metabolism. In: Snell K, Mullock B, eds. Biochemical toxicology: a practical approach. IRL Press, Oxford, United Kingdom; 183-215.
18. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
19. Omura T, Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239: 2370-2378.
20. Oganesian A, Shilling AD, Young-Sciame R, Tran J, Watanyar A, et al. (2009) Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome p450 and p-glycoprotein activities. Psychopharmacol Bull 42: 47-63.
21. Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, et al. (2009) Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 29: 39-43.
22. Nichols AI, Richards LS, Behrle JA, Posener JA, McGrory SB, et al. (2011) The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment. Int J Clin Pharmacol Ther 49: 3-13.
23. Silkey B, Preskorn SH, Golbeck A, Shah R, Neff M, et al. (2005) Complexity of medication use in the Veterans Affairs healthcare system: part II. Antidepressant use among younger and older outpatients. J Psychiatr Pract 11: 16-26.
24. Preskorn SH, Nichols AI, Paul J, Patroneva AL, Helzner EC, et al. (2008) Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. J Psychiatr Pract 14: 368-378.